Edition:
United States

TearLab Corp (TLB.TO)

TLB.TO on Toronto Stock Exchange

0.54CAD
15 Jan 2018
Change (% chg)

-- (--)
Prev Close
$0.54
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,625
52-wk High
$10.10
52-wk Low
$0.46

Latest Key Developments (Source: Significant Developments)

Tearlab corporation provides update on U.S. regulatory strategy for Tearlab Discovery™ System
Tuesday, 17 Oct 2017 07:30am EDT 

Oct 17 (Reuters) - Tearlab Corp ::Tearlab Corporation provides update on U.S. Regulatory strategy for Tearlab Discovery™ System.Tearlab Corp says it has elected to pursue initial U.S. FDA clearance of a test card measuring a single inflammatory biomarker, MMP-9, in combination with co's osmolarity test​.Tearlab - ‍ elected to pursue initial FDA clearance of test card measuring a single inflammatory biomarker, MMP-9, in combination with osmolarity test​.Tearlab Corp - previously planned to seek clearance of a test card containing a total of two inflammatory biomarkers plus osmolarity to aid in diagnosis and management of dry eye disease​.Tearlab - ‍believes revised strategy can reduce review period of application since inflammatory biomarker selected, MMP-9, has fda cleared predicate​.Tearlab Corp - ‍change in regulatory strategy is not expected to impact prior guidance in relation to timing of filing of co's FDA 510(K) application for clearance of Tearlab Discovery System​.Tearlab corp says it believes revised strategy can reduce review period of application since inflammatory biomarker selected, MMP-9, has an FDA cleared predicate​.Tearlab Corp - ‍company remains on track to submit its FDA 510(K) application for Tearlab Discovery System​ by end of 2017.  Full Article

Tearlab - ‍entered amendment to its term loan agreement, dated as of March 2015​
Monday, 16 Oct 2017 07:15am EDT 

Oct 16 (Reuters) - Tearlab Corp :Tearlab Corp - ‍entered into an amendment to its term loan agreement, dated as of March 4, 2015 - SEC filing​.Tearlab Corp - ‍amendment changes required minimum revenue levels under loan agreement from $31 million to $25 million for 2017, from $36 million to $25 million for 2018​.Tearlab- amendment changes required minimum revenue levels under loan agreement from $45 million to $38 million for 2019, from $55 million to $45 million for 2020‍​.  Full Article

TearLab corp - files for offering of up to $15 million - SEC filing‍​
Monday, 21 Aug 2017 05:21pm EDT 

Aug 21 (Reuters) - Tearlab Corp :TearLab Corp - files for offering of up to $15 million - SEC filing‍​.TearLab- offering consists of Class A units consisting of common stock,warrants & Class B units consisting series a convertible preferred stock,warrants.  Full Article

TearLab Corporation Q2 loss per share $0.68
Monday, 14 Aug 2017 04:01pm EDT 

Aug 14 (Reuters) - Tearlab Corp :TearLab Corporation reports second quarter and first half 2017 financial results.Q2 loss per share $0.68.Q2 revenue $7.0 million.TearLab Corp - expects to file its application for clearance of TearLab Discover System, with U.S. Food and Drug Administration in second half of 2017.TearLab Corp - for balance of Q3 2017 and into Q4 2017, company will be taking necessary steps to complete a capital raise.  Full Article

Tearlab announces European regulatory clearance for Tearlab Discovery System
Friday, 21 Jul 2017 07:00am EDT 

July 21 (Reuters) - Tearlab Corp :Tearlab announces European regulatory clearance for next-generation Tearlab Discovery System.  Full Article

TearLab receives Nasdaq listing extension
Wednesday, 21 Jun 2017 05:41pm EDT 

June 21 (Reuters) - TearLab Corp -:TearLab Corp - on June 19, nasdaq hearings panel granted co's request for continued listing, pursuant to extension, through October 6, 2017.  Full Article

Tearlab Corp reports Q1 loss per share of $0.82
Monday, 15 May 2017 04:05pm EDT 

May 15 (Reuters) - Tearlab Corp :Tearlab Corp reports first quarter 2017 financial results.Q1 loss per share $0.82.Q1 earnings per share view $-0.75 -- Thomson Reuters I/B/E/S.Expects to file application for clearance of next generation device, including all three biomarkers, with U.S. FDA by end of Q3.Qtrly net revenues were $6.7 million, compared with $6.8 million for same period in 2016.  Full Article

TearLab osmolarity system receives Brazilian regulatory approval
Friday, 12 May 2017 07:30am EDT 

May 12 (Reuters) - TearLab Corp -:TearLab Osmolarity system receives brazilian regulatory approval.Says approval allows tearlab to begin selling product to aid in diagnosis of dry eye disease (ded) in brazilian market.TearLab Corp - received approval for tearlab osmolarity system from agência nacional de vigilância sanitária in brazil.TearLab Corp - the approval allows tearlab to begin selling product to aid in diagnosis of dry eye disease in brazilian market.  Full Article

Tearlab Corp Q4 loss per share $0.81
Thursday, 9 Mar 2017 04:01pm EST 

Tearlab Corp : Tearlab Corporation reports fourth quarter and year end 2016 financial results . Q4 loss per share $0.81 . Q4 revenue $7.1 million versus I/B/E/S view $7.6 million .Q4 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.  Full Article

Tearlab's In-Vitro diagnostics testing platform got CE marking of device
Monday, 6 Mar 2017 05:20pm EST 

Tearlab Corp :Co's In-Vitro diagnostics testing platform got CE marking of device.  Full Article